| 12 Apr 2011 | The AVERROES Trial – Clinical Implications | De Caterina R., Renda G. | Clinical pharmacology |
| 09 Sep 2008 | New Anticoagulants for Atrial Fibrillation | De Caterina R.*, Renda G., Dalby-Kristensen S.*
| Atrial Fibrillation |
| 08 May 2007 | Stent thrombosis: definitions, mechanisms and prevention | Grove E.C.L. MD and Kristensen S.D. MD, DMSc, FESC
| Cardiovascular Disease Prevention - Risk Assessment and Management |
| 14 Nov 2006 | Anti-thrombotic therapy - news from ESC Congress 2006 / World Congress of Cardiology 2006 | Kristensen S.D FESC
| Cardiovascular Disease Prevention - Risk Assessment and Management |
| 29 May 2006 | Aspirin resistance: a risk factor predicting acute vascular events? | Poulsen TS. and Kristensen SD. FESC
| Cardiovascular Disease Prevention - Risk Assessment and Management |
| 04 Apr 2006 | Therapeutic Strategies in Multiple Vessel Coronary Artery Disease | La Manna A. and Di Mario C. FESC
| Thromboembolic Venous Disease |
| 13 Dec 2005 | Oral anti-platelet therapy and coronary stenting | Dr. S.D. Kristensen*, Dr F. Andreotti, Prof. K. Huber, Prof. R. De Caterina.
*Aarhus, Denmark
Chairperson of the Working Group on Thrombosis
| Clinical pharmacology |
| 01 Feb 2005 | The immediate anti-thrombotic therapy in patients with acute coronary syndromes. | Huber K. FESC, De Caterina R. FESC and Kristensen SD. FESC
| Acute Coronary Syndromes (ACS) |
| 06 Dec 2004 | ST-elevation myocardial infarction – should choice of reperfusion therapy depend on the duration of symptoms? | Kristensen SD. FESC, Huber K. FESC and De Caterina R. FESC
| Acute Coronary Syndromes (ACS) |
| 15 Sep 2004 | n-3 fatty acids in the secondary prevention of coronary heart disease | De Caterina R. FESC, Schmidt EB. FESC, Kristensen SD. FESC
| Chronic Ischaemic Heart Disease (IHD) |